Status:

TERMINATED

Studying the Effects of Sibutramine on Eating Behavior

Lead Sponsor:

New York State Psychiatric Institute

Collaborating Sponsors:

AstraZeneca

Conditions:

Obesity

Eligibility:

All Genders

18-60 years

Phase:

PHASE4

Brief Summary

Obesity is a major public health concern, and the search for useful pharmacologic interventions is ongoing. This study aims to develop a comprehensive series of assessments to directly assess eating b...

Detailed Description

We will recruit 48 moderately obese men and women seeking weight-loss treatment to participate in a 3-week, randomized, double-blind, cross-over trial of sibutramine 15mg or placebo daily. At the end ...

Eligibility Criteria

Inclusion

  • moderately obese
  • stable weight for a minimum of 3 months
  • systolic blood pressure less than or equal to 140 mm Hg
  • diastolic blood pressure less than or equal to 90 mm Hg
  • pulse less than or equal to 95 beats per minute
  • English language proficiency

Exclusion

  • on medications known to affect appetite, weight, or metabolism
  • current or past history of: binge eating disorder, anorexia nervosa or bulimia nervosa, major depression
  • current or past evidence of psychosis, bipolar illness
  • current or past history of alcohol or drug abuse or dependence
  • known history of learning disorder or developmental disability
  • current or past attention deficit hyperactivity disorders
  • low platelet count
  • current diabetes mellitus
  • uncontrolled asthma, or controlled only with oral steroids
  • hypothyroidism not adequately treated
  • pregnancy, planning to become pregnant, or lactation within the previous 6 months
  • history of neurological disorder or injury
  • history of moderate or severe head injury
  • waist circumference greater than 188 cm
  • indwelling metallic object, non-removable metal jewelery, medicinal patch or recent metallic ink tattoo
  • pacemaker
  • metallic implants
  • medication patches
  • significant claustrophobia
  • color blindness

Key Trial Info

Start Date :

February 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2010

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT01170364

Start Date

February 1 2009

End Date

October 1 2010

Last Update

August 30 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

New York State Psychiatric Institute

New York, New York, United States, 10032